Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibe Therapeutics Inc.

www.antibethera.com

Latest From Antibe Therapeutics Inc.

Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures

The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.

Asia Pacific Deals

Pipeline Watch: Phase III Progress With Tecentriq, Rolontis And ADV7103

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Pipeline Watch: Phase III Progress With Eylea, Tecentriq And HTX-011

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Dental & Oral Products
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Antibe Therapeutics Inc.
  • Senior Management
  • Alain Wilson, CFO
    Dan Legault , Pres.
    John Wallace , PhD, CSO
    David Vaughan, PhD, Chief Dev. Officer
    Scott Curtis, VP, Bus. Dev.
  • Contact Info
  • Antibe Therapeutics Inc.
    Phone: (416) 473-4095
    15 Prince Arthur Ave.
    Toronto , M5R 1B2
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register